|
Name |
Palmarumycin CP4
|
Molecular Formula | C20H16O5 | |
IUPAC Name* |
(4R,4aS)-4,8-dihydroxyspiro[2,3,4,4a-tetrahydronaphthalene-5,3'-2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene]-1-one
|
|
SMILES |
C1CC(=O)C2=C(C=CC3([C@@H]2[C@@H]1O)OC4=CC=CC5=C4C(=CC=C5)O3)O
|
|
InChI |
InChI=1S/C20H16O5/c21-12-7-8-14(23)19-18(12)13(22)9-10-20(19)24-15-5-1-3-11-4-2-6-16(25-20)17(11)15/h1-6,9-10,14,19,22-23H,7-8H2/t14-,19-/m1/s1
|
|
InChIKey |
KHWCPGYSJZWUAY-AUUYWEPGSA-N
|
|
Synonyms |
Palmarumycin CP4; (8'R,8'aS)-6',7',8',8'a-Tetrahydro-4',8'-dihydroxyspiro[naphtho[1,8-de]-1,3-dioxin-2,1'(5'H)-naphthalen]-5'-one
|
|
CAS | NA | |
PubChem CID | 10042618 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 336.3 | ALogp: | 3.0 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 76.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 25 | QED Weighted: | 0.765 |
Caco-2 Permeability: | -4.778 | MDCK Permeability: | 0.00002890 |
Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.021 |
Blood-Brain-Barrier Penetration (BBB): | 0.705 | Plasma Protein Binding (PPB): | 95.63% |
Volume Distribution (VD): | 0.803 | Fu: | 2.15% |
CYP1A2-inhibitor: | 0.561 | CYP1A2-substrate: | 0.371 |
CYP2C19-inhibitor: | 0.722 | CYP2C19-substrate: | 0.377 |
CYP2C9-inhibitor: | 0.475 | CYP2C9-substrate: | 0.865 |
CYP2D6-inhibitor: | 0.693 | CYP2D6-substrate: | 0.158 |
CYP3A4-inhibitor: | 0.726 | CYP3A4-substrate: | 0.323 |
Clearance (CL): | 7.644 | Half-life (T1/2): | 0.526 |
hERG Blockers: | 0.038 | Human Hepatotoxicity (H-HT): | 0.87 |
Drug-inuced Liver Injury (DILI): | 0.179 | AMES Toxicity: | 0.782 |
Rat Oral Acute Toxicity: | 0.789 | Maximum Recommended Daily Dose: | 0.757 |
Skin Sensitization: | 0.2 | Carcinogencity: | 0.89 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.041 |
Respiratory Toxicity: | 0.941 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003416 | 0.618 | D06TJJ | 0.286 | ||||
ENC003642 | 0.614 | D06ZEE | 0.270 | ||||
ENC005581 | 0.578 | D08CCE | 0.269 | ||||
ENC003345 | 0.576 | D00JRA | 0.250 | ||||
ENC003414 | 0.559 | D02TJS | 0.243 | ||||
ENC002537 | 0.533 | D0H6QU | 0.240 | ||||
ENC002531 | 0.532 | D09LDR | 0.240 | ||||
ENC003287 | 0.532 | D05MQK | 0.238 | ||||
ENC003288 | 0.532 | D0O6IZ | 0.237 | ||||
ENC003290 | 0.527 | D04BNP | 0.236 |